New Concepts in Anxiety

Front Matter....Pages i-xii
Anxiety and Its Therapy: Today and Tomorrow....Pages 1-12
The Neuropsychology of Anxiety and Tolerance for Stress....Pages 13-38
Immunological Ecology of Anxiety and Stress....Pages 39-45
The Neuropharmacology of 5-HT in Anxiety....Pages 46-55
The Role of Serotonin in Anxiety: Behavioural Approaches....Pages 56-73
5-HT Receptor Mechanisms in Human Anxiety....Pages 74-93
5-HT1A Receptors in Anxiety....Pages 94-129
5-Hydroxytryptamine1A (5-HT1A) Receptor Responsivity in Anxiety Disorders and Depression....Pages 130-144
Modulations of Central Serotonergic Neurotransmission by Chronic Ipsapirone in the Rat....Pages 145-153
Anxiogenic and Other Effects of mCPP, a 5-HT, 1C Agonist....Pages 154-167
Platelet [3H]-paroxetine and [3H]-imipramine binding in zacopride-treated patients with generalized anxiety disorder: preliminary results....Pages 168-174
Platelet Imipramine Binding Bmax Predicts Response to Anxiety in Alprazolam-Treated Panic Disorder Patients....Pages 175-184
Ondansetron: A Novel Anti-anxiety Agent....Pages 185-189
Is Receptor Heterogeneity Relevant to the Anxiolytic Actions of Benzodiazepine Receptor Ligands?....Pages 190-202
Central Benzodiazepine Receptors: Quantitative Positron Emission Tomography Study in Healthy Subjects and Anxious Patients....Pages 203-210
GABA-lndependent Mechanisms of Benzodiazepine Action....Pages 211-236
Benzodiazepine Dependence....Pages 237-255
Benzodiazepine Withdrawal Reactions: Distinction from a Recurrence of the Pretreatment Symptoms, Prevention and Treatment....Pages 256-262
Withdrawal Symptoms After long-term Benzodiazepine Dependency and Comparison of the Abuse Potential of Two Benzodiazepine Receptor Agonists....Pages 263-267
Effects of Repeated Administration of Diazepam to Rats on Locomotor Activity, Elevated Plus-maze and Various Brain Receptors....Pages 268-276
Comparison of Acute and Chronic Treatment of Diazepam and Ritanserin in the Elevated Plus-maze Model of Anxiety....Pages 277-287
Neurotransmitters in the Dorsal Periaqueductal Grey and Animal Models of Panic Anxiety....Pages 288-312
Cholecystokinjn Tetrapeptide: a Provocation Agent for Research in Panic Disorder?....Pages 313-319
The Lateral Septum as an Anxiety-inhibiting Structure: a New Model for Anxiolytic Action....Pages 320-326
Anticonvulsant Effect of Some Anxiolytic Drugs on Two Models of Sound-induced Seizures in Mice....Pages 327-331
Anxiogenic Effects of Scopolamine Observed in Rats in the Elevated Plus-maze....Pages 332-337
Effect of Anxiolytic and Hypnotic Drugs on Sleep Circadian Rhythms in the Rat....Pages 338-346
The Implication of Noradrenaline in Anxiety....Pages 347-365
Excitatory Amino Acids and Anxiety....Pages 366-381
Are Glutamatergic Pathways Involved in the Pathophysiology of Anxiety?....Pages 382-394
Antianxiety Treatments and Human Memory....Pages 395-405
Anxiety and Cognition....Pages 406-417
Cognitive Factors in Clinical Anxiety: Potential Relevance to Therapy....Pages 418-433
The Effects of Trait-anxiety on Anagram Solution Times....Pages 434-439
Bidirectional Activity of Benzodiazepine-receptor Ligands in Cognitive Functions in Humans....Pages 440-457
Panic Disorders: Relationship to Anxiety and Cognitive Processes....Pages 458-468
Early Clinical Testing of Non-benzodiazepine Anxiolytics....Pages 469-480
Back Matter....Pages 481-491